Sun's Plant Review Blueprint: Balance And Fall-Backs
This article was originally published in Scrip
Executive Summary
India's top drug firm, Sun Pharmaceutical Industries, expects to use a "judicious balance" between reducing complexities in its vast manufacturing network and maintaining adequate and "fall-back" capacities for "critical" products as part of rationalization efforts aimed at deriving synergy benefits from the Ranbaxy acquisition.